The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant.
Breakthrough infections
COVID-19
ORCHESTRA
Population-based cohort study
SARS-CoV-2
Sero-incidence
Sero-prevalence
Vaccination status
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
08
02
2023
accepted:
30
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe. Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies. The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found. Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron.
Sections du résumé
BACKGROUND
BACKGROUND
Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe.
METHODS
METHODS
Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies.
RESULTS
RESULTS
The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found.
CONCLUSIONS
CONCLUSIONS
Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron.
Identifiants
pubmed: 37442952
doi: 10.1186/s12879-023-08435-1
pii: 10.1186/s12879-023-08435-1
pmc: PMC10339498
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
466Investigateurs
Mohamed Ibraheem Mohamed Ahmed
(MIM)
Emad Alamoudi
(E)
Jared Anderson
(J)
Valeria Baldassarre
(V)
Maximilian Baumann
(M)
Marc Becker
(M)
Franziska Bednarski
(F)
Marieke Behlen
(M)
Olimbek Bemirayev
(O)
Jessica Beyerl
(J)
Patrick Bitzer
(P)
Rebecca Böhnlein
(R)
Isabel Brand
(I)
Anna Brauer
(A)
Vera Britz
(V)
Jan Bruger
(J)
Franziska Bünz
(F)
Friedrich Caroli
(F)
Josephine Coleman
(J)
Lorenzo Contento
(L)
Alina Czwienzek
(A)
Flora Deák
(F)
Maximilian N Diefenbach
(MN)
Paulina Diepers
(P)
Anna Do
(A)
Gerhard Dobler
(G)
Jürgen Durner
(J)
Tabea Eser
(T)
Ute Eberle
(U)
Judith Eckstein
(J)
Philine Falk
(P)
Manuela Feyereisen
(M)
Volker Fingerle
(V)
Stefanie Fischer
(S)
Jonathan Frese
(J)
Felix Forster
(F)
Günter Fröschl
(G)
Otto Geisenberger
(O)
Mercè Garí
(M)
Marius Gasser
(M)
Sonja Gauder
(S)
Raffaela Geier
(R)
Kristina Gillig
(K)
Christof Geldmacher
(C)
Keisha Gezgin
(K)
Leonard Gilberg
(L)
Kristina Gillig
(K)
Philipp Girl
(P)
Elias Golschan
(E)
Vitus Grauvogl
(V)
Jessica Michelle Guggenbuehl Noller
(JMG)
Elena Maria Guglielmini
(EM)
Pablo Gutierrez
(P)
Anselm Haderer
(A)
Celina Halfmann
(C)
Lena Hartinger
(L)
Timm Haselwarter
(T)
Jan Hasenauer
(J)
Alejandra Hernandez
(A)
Luca Heller
(L)
Arlett Heiber
(A)
Matthias Herrmann
(M)
Leah Hillari
(L)
Stefan Hillmann
(S)
Christian Hinske
(C)
Janna Hoefflin
(J)
Tim Hofberger
(T)
Michael Höfinger
(M)
Larissa Hofmann
(L)
Sacha Horn
(S)
Kristina Huber
(K)
Christian Janke
(C)
Lilian Karger
(L)
Ursula Kappl
(U)
Antonia Keßler
(A)
Zohaib Khan
(Z)
Charlotte Kiani
(C)
Isabel Klugherz
(I)
Norah Kreider
(N)
Johanna Kresin
(J)
Arne Kroidl
(A)
Pratik Kunder
(P)
Magdalena Lang
(M)
Clemens Lang
(C)
Silvan Lange
(S)
Ekaterina Lapteva
(E)
Michael Laxy
(M)
Reiner Leidl
(R)
Leopold Liedl
(L)
Felix Lindner
(F)
Xhovana Lucaj
(X)
Elisabeth Lucke
(E)
Fabian Luppa
(F)
Alexandra Sophie Nafziger
(AS)
Alexander Maczka
(A)
Petra Mang
(P)
Alisa Markgraf
(A)
Paula Matcau
(P)
Rebecca Mayrhofer
(R)
Anna-Maria Mekota
(AM)
Dafni Metaxa
(D)
Emily Mohr
(E)
Hannah Müller
(H)
Katharina Müller
(K)
Nathalia Nascimento
(N)
Kasimir Niermeyer
(K)
Sophia Nikolaides
(S)
Leonie Pattard
(L)
Claire Pleimelding
(C)
Michel Pletschette
(M)
Viona Poll
(V)
Stephan Prückner
(S)
Kerstin Puchinger
(K)
Konstantin Pusl
(K)
Elba Raimúndez
(E)
Julius Raschka
(J)
Jakob Reich
(J)
Christina Reinkemeyer
(C)
Camilla Rothe
(C)
Viktoria Ruci
(V)
Elmar Saathoff
(E)
Nicole Schäfer
(N)
Paul Schandelmaier
(P)
Benedikt Schluse
(B)
Annika Schneider
(A)
Lara Schneider
(L)
Sophie Schultz
(S)
Mirjam Schunk
(M)
Lars Schwettmann
(L)
Josefin Sedlmeier
(J)
Linda Sintu-Sempta
(L)
Alba Soler
(A)
Peter Sothmann
(P)
Katharina Strobl
(K)
Aida Strüber
(A)
Laura Strüber
(L)
Jeni Tang
(J)
Fabian Theis
(F)
Verena Thiel
(V)
Eva Thumser
(E)
Niklas Thur
(N)
Julian Ullrich
(J)
Vincent Vollmayr
(V)
Emilia Von Lovenberg
(E)
Jonathan Von Lovenberg
(J)
Carsten Vos
(C)
Julia Waibel
(J)
Claudia Wallrauch
(C)
Nikolas Weigl
(N)
Roman Wölfl
(R)
Julia Wolff
(J)
Pia Wullinger
(P)
Tobias Würfel
(T)
Patrick Wustrow
(P)
Sabine Zange
(S)
Eleftheria Zeggini
(E)
Anna Zielke
(A)
Thorbjörn Zimmer
(T)
Thomas Zimmermann
(T)
Anna Zielke
(A)
Lea Zuche
(L)
Informations de copyright
© 2023. The Author(s).
Références
Int J Environ Res Public Health. 2021 Mar 30;18(7):
pubmed: 33808249
PLoS One. 2020 Aug 14;15(8):e0237833
pubmed: 32797108
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34376550
J Clin Virol. 2022 Apr;149:105130
pubmed: 35305377
EClinicalMedicine. 2020 Aug;25:100466
pubmed: 32840492
Ir J Med Sci. 2023 Apr;192(2):751-756
pubmed: 35711013
Eur J Epidemiol. 2021 Dec;36(12):1237-1240
pubmed: 34591202
Adv Drug Deliv Rev. 2021 May;172:314-338
pubmed: 33482248
BMC Med Res Methodol. 2020 Jul 9;20(1):187
pubmed: 32646374
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMC Public Health. 2004 Jun 03;4:19
pubmed: 15176983
Trop Med Infect Dis. 2022 Nov 14;7(11):
pubmed: 36422926
EBioMedicine. 2021 Aug;70:103502
pubmed: 34333234
Lancet Reg Health Eur. 2022 Sep;20:100452
pubmed: 35791335
Nat Rev Immunol. 2022 Jan;22(1):57-65
pubmed: 34876702
JAMA. 2022 Jan 11;327(2):179-181
pubmed: 34914825
J Gen Virol. 2021 Oct;102(10):
pubmed: 34623233
PLoS Med. 2022 Nov 22;19(11):e1004037
pubmed: 36413551
Front Public Health. 2021 Mar 04;9:591717
pubmed: 33748056
BMC Public Health. 2020 Jun 30;20(1):1036
pubmed: 32605549
BMC Infect Dis. 2021 Sep 8;21(1):925
pubmed: 34493217
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Epidemiol Infect. 2009 May;137(5):654-61
pubmed: 18840319
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141